| Ytd | 3.75% | |
| 1y | -17.61% |
| Open | 68.16 | Prev Close | 67.35 | Low | 67.87 | High | 69.66 | Mkt Cap | 26.57B |
| Vol | 4.75M | Avg Vol | 5.65M | EPS | 2.33 | P/E | 29.55 | Forward P/E | 22.34 |
| Beta | 1.44 | Short Ratio | 2.40 | Inst. Own | 102.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 67.51 | 200-d Avg | 67.16 | 1yr Est | 85.24 |
DXCM News
DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes mark
DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it
Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo
Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an
FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G
Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise
https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose
TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t
Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr
DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients n
Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care
Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ
CONNECT study will demonstrate Dexcom CGM benefits for adults with Type 2 diabetes not using insulin